Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>AmerisourceBergen Corporation managed to surpass the revenue and earnings expectations of Wall Street in the last quarter.</li><li>The company observed continued progress across its businesses in the quarter, producing significant revenue growth.</li><li>We give AmerisourceBergen Corporation a 'Hold' rating with a revised target price.</li></ul>

AmerisourceBergen Corporation managed to surpass the revenue and earnings expectations of Wall Street in the last quarter.The company observed continued progress across its businesses in the quarter, producing significant revenue growth.We give AmerisourceBergen Corporation a 'Hold' rating with a revised target price.

AmerisourceBergen Corporation: 4 Pillars Behind Their Revenue Growth! - Financial Forecasts

<ul><li>AmerisourceBergen managed to exceed analyst expectations in terms of revenue as well as earnings.</li><li>Their successes continue to highlight the worth of their pharmaceutical-centric strategy, which includes critical strategic relationships, specialist leadership, and full global commercialization services.</li><li>OneOncology's practice management services also complement the company's existing inventory management, practice analytics, and clinical trial support capabilities.</li></ul>

AmerisourceBergen managed to exceed analyst expectations in terms of revenue as well as earnings.Their successes continue to highlight the worth of their pharmaceutical-centric strategy, which includes critical strategic relationships, specialist leadership, and full global commercialization services.OneOncology's practice management services also complement the company's existing inventory management, practice analytics, and clinical trial support capabilities.

AmerisourceBergen Corporation: Can The OneOncology Investment Become A Game Changer? – Key Drivers

Credit

<ul><li>AmerisourceBergen is a major pharmaceutical sourcing and distribution services provider in the U.S.</li><li>The company has reasonably strong financials and a dominant position in an oligopolistic market.</li><li>The management believes that the acquisition of PharmaLex will help the company assist pharma and biotech companies.</li></ul>

AmerisourceBergen is a major pharmaceutical sourcing and distribution services provider in the U.S.The company has reasonably strong financials and a dominant position in an oligopolistic market.The management believes that the acquisition of PharmaLex will help the company assist pharma and biotech companies.

AmerisourceBergen Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

Equity Capital Markets

<ul><li>This is our first report on major pharmaceutical sourcing and distribution services provider, AmerisourceBergen.</li><li>Among major updates, AmerisourceBergen added PharmaLex to its portfolio of specialty solutions to expand its capabilities.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

This is our first report on major pharmaceutical sourcing and distribution services provider, AmerisourceBergen.Among major updates, AmerisourceBergen added PharmaLex to its portfolio of specialty solutions to expand its capabilities.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

AmerisourceBergen Corporation: Initiation of Coverage – Acquisition of PharmaLex & Key Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares Russell 2000 ETF / Technical Analysis

<ul>
<li>The bifurcation between large-cap growth and small-caps that we discussed last week has continued, where small-caps have generally not been participating in the rally.</li>
<li>As we said last week, this bifurcation can continue, but it is not the type of breadth that supports a sustainable new bull market.</li>
<li>We need to see the Russell 2000 (IWM) stay above $209 in order to have confidence that the bottom is in. Meanwhile, stick with the commodity and defensive Sectors.</li>
</ul>


The bifurcation between large-cap growth and small-caps that we discussed last week has continued, where small-caps have generally not been participating in the rally.
As we said last week, this bifurcation can continue, but it is not the type of breadth that supports a sustainable new bull market.
We need to see the Russell 2000 (IWM) stay above $209 in order to have confidence that the bottom is in. Meanwhile, stick with the commodity and defensive Sectors.


Bifurcation Continues; Banks, Semiconductors, Small-Caps, Homebuilders Remain Concerns

United States

Cencora, Inc. operates as a pharmaceutical company. The Company offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers. Cencora distributes its products internationally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cencora (COR US)

AmerisourceBergen Corporation: 4 Pillars Behind Their Revenue Growth! - Financial Forecasts

AmerisourceBergen Corporation managed to surpass the revenue and earnings expectations of Wall Street in the last quarter. The company observed...

Baptista Research

AmerisourceBergen Corporation: Can The OneOncology Investment Become A Game Changer? – Key Drivers

AmerisourceBergen managed to exceed analyst expectations in terms of revenue as well as earnings. Their successes continue to highlight the worth...

Baptista Research

AmerisourceBergen Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

AmerisourceBergen is a major pharmaceutical sourcing and distribution services provider in the U.S. The company has reasonably strong financials...

Baptista Research

AmerisourceBergen Corporation: Initiation of Coverage – Acquisition of PharmaLex & Key Drivers

This is our first report on major pharmaceutical sourcing and distribution services provider, AmerisourceBergen. Among major updates,...

Baptista Research

Bifurcation Continues; Banks, Semiconductors, Small-Caps, Homebuilders Remain Concerns

Several indexes remain below key resistance, including 4600 on $SPX, $110 on $QQEW, $209 on $IWM, $111 on $IJR, $507 on the $SOX index $SOXX, $73...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)